Profound Medical Corp. (PROF)

Market Cap	98.14M
Revenue (ttm)	4.87M
Net Income (ttm)	-24.57M
Shares Out	20.85M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,650
Open	4.69
Previous Close	4.67
Day's Range	4.5 - 4.76
52-Week Range	3.1 - 12.27
Beta	1.81
Analysts	Buy
Price Target	12.64 (+167.8%)
Earnings Date	Nov 3, 2022

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief assoc...

• Industry: Health Care Equipment & Supplies
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: PROF

Full Company Profile

Financial Performance

In 2021, PROF's revenue was 6.87 million, a decrease of -5.90% compared to the previous year's 7.30 million. Losses were -30.52 million, 25.0% more than in 2020.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PROF stock is "Buy." The 12-month stock price forecast is 12.64, which is an increase of 167.80% from the latest price.

Price Target

$12.64

(167.80% upside)

Analyst Consensus: Buy

Stock Forecasts